Sitemap
Update: July 26th, 2009
Sitemap of posts on Orshe.com
Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
Posts
- Category: Wall Street Journal (continued)
- A.M. Vitals: FDA Says Heavy Actos Use May Be Tied to Bladder Cancer
- A.M. Vitals: FDA to Bolster Painkiller Control Efforts
- A.M. Vitals: FDA to Regulate Electronic Cigarettes as Tobacco Products
- A.M. Vitals: FDA Wants More Data on Diabetes Drug from Bristol-Myers, AstraZeneca
- A.M. Vitals: FDA Warns On Inferior Vena Cava Filters
- A.M. Vitals: Federal Appeals Courts Set to Hear Health Law Arguments
- A.M. Vitals: Federal Medical Privacy Rules Go Back for Do-Over
- A.M. Vitals: Federal Prosecutors Want $1 Billion From Johnson & Johnson
- A.M. Vitals: Feds Won’t Try to Exclude Forest’s Solomon From Government Business
- A.M. Vitals: Figuring Out How to Handle Access to Bird-Flu Data
- A.M. Vitals: Finally! Sanofi and Genzyme Talk Takeover
- A.M. Vitals: Food Companies Cutting Calories, Cellphones and Health
- A.M. Vitals: France, Germany Halt Use of Takeda’s Actos
- A.M. Vitals: Gene Manipulation Improves Alzheimer’s Symptoms in Mice
- A.M. Vitals: Gene Therapy Gets a Boost
- A.M. Vitals: Gene Therapy Treats Hemophilia B in Small Study
- A.M. Vitals: Genentech’s Avastin and Lucentis May Work Similarly in Eyes
- A.M. Vitals: Genetic Immunotherapy For Leukemia Holds Promise
- A.M. Vitals: Genzyme and Sanofi Agree on Deal — In Principle
- A.M. Vitals: Genzyme Considers a Way Around Campath Impasse
- A.M. Vitals: Genzyme Factory Fixes Will Take Longer Than Thought
- A.M. Vitals: Genzyme Points to MS Drug As Sign Sanofi Bid is Too Low
- A.M. Vitals: Genzyme Rejects Takeover Offer From Sanofi-Aventis
- A.M. Vitals: Genzyme Says Sanofi Needs to Cough Up More Cash
- A.M. Vitals: Genzyme to Explore ‘Alternatives’ to Sanofi Bid
- A.M. Vitals: Genzyme, Sanofi Are Talking, But Nothing’s Guaranteed
- A.M. Vitals: Gilead Pill Cuts Risk of HIV Infection in Study
- A.M. Vitals: Gilead to Pay About $10.4 Billion For Pharmasset
- A.M. Vitals: Glaxo Takes $2.4 Billion Charge Over Lawsuits
- A.M. Vitals: Government Issues Rules on State Insurance Exchanges
- A.M. Vitals: Ground-Turkey Salmonella Outbreak Raises Antibiotics Question
- A.M. Vitals: Gut Linked to Non-Digestive Ailments
- A.M. Vitals: HCA’s Results Show Sluggish Economy’s Effects on Hospitals
- A.M. Vitals: Health Insurers Diversify As Overhaul Trims Margins
- A.M. Vitals: Health Law’s Insurance Waiver Program to End in September
- A.M. Vitals: Health-Care Execs Have Their Own Medicare Proposal
- A.M. Vitals: Health-Care Industry Has a Wish List for Republicans
- A.M. Vitals: Health-Law Debate Turns to Defining ‘Essential’ Care
- A.M. Vitals: Health-Overhaul Law Will Have ‘Moderate’ Spending Effect
- A.M. Vitals: Heart Health Report Card, Penalties for Smokers and Cheese Vs. Butter
- A.M. Vitals: HHS Will Exercise ‘Discretion’ on McDonald’s Insurance
- A.M. Vitals: Hospitals Face Consequences of Interest-Rate Bets
- A.M. Vitals: House Votes to Repeal Health Law’s Reporting Provision
- A.M. Vitals: House Votes to Repeal Health-Care Law
- A.M. Vitals: How Men and Women Sleep Differently
- A.M. Vitals: How to Treat a Kid’s Ruptured Appendix
- A.M. Vitals: Human Stem Cells Ease Parkinson’s Symptoms in Rodents
- A.M. Vitals: Humana Profit Up 21% On New Enrollment
- A.M. Vitals: In Louisville, Ky., Surgeons National Drivers of Spinal Fusion Surgery
- A.M. Vitals: Insurance Executives Say New Benefits Mean Higher Rates
- A.M. Vitals: Insurers Join the Electronic Medical Records Party
- A.M. Vitals: Investigating IMRT For Prostate Cancer
- A.M. Vitals: It’s Open Enrollment Season; Look for High Deductibles
- A.M. Vitals: J&J Aims to Step Into Blood-Thinner Market
- A.M. Vitals: J&J and Synthes Agree to $21.3 Billion Deal
- A.M. Vitals: J&J Documents Raise Questions About 2009 Recall
- A.M. Vitals: J&J Latest to See Drug Shortage
- A.M. Vitals: J&J Reaches Agreement to Buy Crucell For $2.4 Billion
- A.M. Vitals: J&J Sets Record With Corporate Bond Rates
- A.M. Vitals: J&J Shakes Up Oversight of McNeil Unit
- A.M. Vitals: J&J Subject to Five Years of FDA Oversight
- A.M. Vitals: J&J to Settle Texas Risperdal Suit For $158 Million
- A.M. Vitals: J&J Trims Bonuses Due to ‘Mixed Performance’
- A.M. Vitals: J&J, Bayer Anticlotting Drug Shows Promise in Heart-Attack Patients
- A.M. Vitals: J&J, Merck Reach Agreement on Arthritis Drugs
- A.M. Vitals: J&J-FDA Tussle Highlights Medical Device Approval Debate
- A.M. Vitals: J&J’s Metal-on-Metal Hips Subject of 1,000 Lawsuits
- A.M. Vitals: J&J’s Plan to Fix Plant Includes 300 Layoffs
- A.M. Vitals: J&J’s Weldon Saw 7% Drop in Total Compensation Last Year
- A.M. Vitals: Japan Finds Radiation Cleanup Difficult
- A.M. Vitals: Japan Puts Two Pfizer, Sanofi Vaccines on Hold
- A.M. Vitals: Japanese Panel Says Pfizer, Sanofi Vaccines Not Likely Tied to Deaths
- A.M. Vitals: Johnson & Johnson Focuses on Quality Control
- A.M. Vitals: Johnson & Johnson Recalls Kids’ Benadryl, Motrin
- A.M. Vitals: Johnson & Johnson’s Flu Caplets to Return to Shelves
2009 -